NBSE
Income statement / Annual
Last year (2022), NeuBase Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, NeuBase Therapeutics, Inc.'s net income was -$34.23 M.
See NeuBase Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
09/30/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.26 M
|
$575.52 K
|
$280.46 K
|
$128.37 K
|
$13.90 M
|
$23.78 M
|
$24.60 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$1.26 M
|
-$575.52 K
|
-$280.46 K
|
-$128.37 K
|
-$13.90 M
|
-$23.78 M
|
-$24.60 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.45 M
|
$14.36 M
|
$6.95 M
|
$17.24 M
|
$4.32 M
|
$17.41 M
|
$16.46 M
|
$8.78 M
|
$3.99 M
|
$2.61 M
|
| General & Administrative Expenses |
$11.87 M
|
$12.20 M
|
$10.12 M
|
$9.10 M
|
$3.63 M
|
$5.28 M
|
$7.66 M
|
$7.51 M
|
$5.13 M
|
$2.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.87 M
|
$12.20 M
|
$10.12 M
|
$9.10 M
|
$3.63 M
|
$5.28 M
|
$7.66 M
|
$7.51 M
|
$5.13 M
|
$2.01 M
|
| Other Expenses |
-$166.87 K
|
$450.31 K
|
$412.37 K
|
$0.00
|
$592.58 K
|
$1.17 M
|
-$471.98 K
|
$1.18 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$33.32 M
|
$26.57 M
|
$17.07 M
|
$26.34 M
|
$9.08 M
|
$23.85 M
|
$25.31 M
|
$17.47 M
|
$9.12 M
|
$4.62 M
|
| Cost And Expenses |
$33.32 M
|
$26.57 M
|
$17.07 M
|
$26.34 M
|
$9.08 M
|
$23.85 M
|
$25.31 M
|
$17.47 M
|
$9.12 M
|
$4.62 M
|
| Interest Income |
$148.56 K
|
$12.55 K
|
$7.69
|
$128.95
|
$8.88 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$24.05 K
|
$32.33 K
|
$7.69 K
|
$128.95 K
|
$0.00
|
$30.92 K
|
$1.17 M
|
$5.98 K
|
$5.58 K
|
$4.69 K
|
| Depreciation & Amortization |
$828.45 K
|
$641.37 K
|
$149.51 K
|
$128.37 K
|
$1.12 M
|
$1.17 M
|
$1.19 M
|
$1.18 M
|
$466.31 K
|
$91.15 K
|
| EBITDA |
-$32.92 M |
-$25.92 M |
-$17.23 M |
-$26.70 M |
-$3.13 M |
-$22.75 M |
-$24.12 M |
-$16.39 M |
-$8.67 M |
-$4.53 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$458.11 K
|
$1.16 M
|
-$315.21 K
|
-$621.84 K
|
-$12.74 M
|
-$30.93 K
|
-$459.88 K
|
$2.61 M
|
$0.00
|
-$1.03 M
|
| Income Before Tax |
-$33.78 M
|
-$25.41 M
|
-$17.38 M
|
-$26.96 M
|
-$13.24 M
|
-$23.81 M
|
-$25.77 M
|
-$15.20 M
|
-$9.13 M
|
-$5.65 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$458.11 K
|
$258.11 K
|
-$123.27 K
|
$128.95 K
|
$8.98 M
|
-$109.24 K
|
$459.88 K
|
$0.00
|
-$8.48 K
|
$0.00
|
| Net Income |
-$34.23 M
|
-$25.67 M
|
-$17.26 M
|
-$27.09 M
|
-$13.24 M
|
-$23.81 M
|
-$25.77 M
|
-$15.20 M
|
-$9.13 M
|
-$5.65 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-21.08 |
-18.8 |
-17.6 |
-65.49 |
-93.57 |
-212.74 |
-328.76 |
-214.02 |
-164.95 |
-120.86 |
| EPS Diluted |
-21.08 |
-18.8 |
-17.6 |
-65.49 |
-93.57 |
-212.74 |
-328.76 |
-214.02 |
-164.95 |
-120.86 |
| Weighted Average Shares Out |
$1.62 M
|
$1.37 M
|
$981.01 K
|
$413.59 K
|
$141.46 K
|
$111.93 K
|
$78.37 K
|
$71.01 K
|
$55.35 K
|
$46.77 K
|
| Weighted Average Shares Out Diluted |
$1.62 M
|
$1.37 M
|
$981.01 K
|
$413.59 K
|
$141.46 K
|
$111.93 K
|
$78.37 K
|
$71.01 K
|
$55.35 K
|
$46.77 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
